5 Stocks To Trade on Thursday
Investors have five stocks to consider trading today. In the lithium mining sector, Albemarle (ALB) continued its breakout. ALB stock has consolidated in the $60 range since April.UBS noted that prolonged supply disruptions in China could impact up to 15% of lithium production. Sigma Lithium (SGML), SQM (SQM), and Lithium Americas (LAC) are also worthwhile speculative trades.Trade #2: Paramount Skydance (PSKY) is in danger of re-testing lower prices in the low teens. The stock lost 6.5% on Wednesday on no news. In November, the firm might cut a significant number of jobs, as The New York Post reported last Friday.For #3, J.M. Smucker (SJM) fell over 4% to close at $105.67. It posted soft guidance in its fiscal Q4 earnings report. Although comparable net sales increased by 6%, net pricing for peanut butter offset its growth.SJM stock is under pressure after full-year net sales are expected to be 3% - 5%. This is higher than its prior outlook.Fourth, the stumble in Palantir (PLTR) shares continued. Fortunately, the stock has an upward support level at the 50-day simple moving average.The fifth stock to watch is SBA Communications (SBAC). Shares “double-topped” at $245. It lost $10.71 a share to close at $208.13. BofA Securities downgraded the stock. It viewed AT&T’s (T) deal with EchoStar (SATS) would raise SBAC’s churn rates.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


